Goldman Sachs’s Acadia Pharmaceuticals ACAD Stock Holding History

Goldman Sachs’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-89,800	Closed	-$1.92M	–	6413
2025 Q3	$1.92M	Hold	89,800	–	–	﹤0.01%	4526
2025 Q2	$1.94M	Hold	89,800	–	–	﹤0.01%	4209
2025 Q1	$1.49M	Sell	89,800 -100	-0.1%	-$1.82K	﹤0.01%	4383
2024 Q4	$1.65M	Hold	89,900	–	–	﹤0.01%	4454
2024 Q3	$1.38M	Hold	89,900	–	–	﹤0.01%	4417
2024 Q2	$1.46M	Buy	+89,900	New	+$1.45M	﹤0.01%	4172
2024 Q1	–	Sell	-46,100	Closed	-$1.44M	–	5522
2023 Q4	$1.44M	Buy	+46,100	New	+$1.1M	﹤0.01%	4172
2021 Q1	–	Sell	-4,000	Closed	-$214K	–	6037
2020 Q4	$214K	Sell	4,000 -30,000	-88%	-$1.49M	﹤0.01%	5055
2020 Q3	$1.4M	Buy	34,000 +10,000	+42%	+$432K	﹤0.01%	3831
2020 Q2	$1.16M	Buy	+24,000	New	+$1.15M	﹤0.01%	3852
2019 Q1	–	Sell	-75,400	Closed	-$1.22M	–	5077
2018 Q4	$1.22M	Hold	75,400	–	–	﹤0.01%	3862
2018 Q3	$1.56M	Sell	75,400 -12,700	-14%	-$200K	﹤0.01%	3754
2018 Q2	$1.34M	Buy	+88,100	New	+$1.57M	﹤0.01%	3883
2017 Q4	–	Sell	-50,000	Closed	-$1.88M	–	6297
2017 Q3	$1.88M	Buy	+50,000	New	+$1.63M	﹤0.01%	4055
2017 Q1	–	Sell	-64,000	Closed	-$1.85M	–	6718
2016 Q4	$1.85M	Buy	+64,000	New	+$1.69M	﹤0.01%	3928
2016 Q3	–	Sell	-20,000	Closed	-$649K	–	6993
2016 Q2	$649K	Sell	20,000 -50,000	-71%	-$1.67M	﹤0.01%	4600
2016 Q1	$1.96M	Buy	70,000 +20,000	+40%	+$436K	﹤0.01%	3489
2015 Q4	$1.78M	Hold	50,000	–	–	﹤0.01%	3740
2015 Q3	$1.65M	Hold	50,000	–	–	﹤0.01%	3989
2015 Q2	$2.09M	Hold	50,000	–	–	﹤0.01%	3785
2015 Q1	$1.63M	Buy	+50,000	New	+$1.72M	﹤0.01%	3981
2013 Q3	–	Sell	-583,800	Closed	-$10.6M	–	6546
2013 Q2	$10.6M	Buy	+583,800	New	+$8.04M	﹤0.01%	2024

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Goldman Sachs's ACAD Position: Q1 2026 in Review

Goldman Sachs reduced its Acadia Pharmaceuticals (ACAD) stake by 0.78% in Q1 2026, selling an estimated $293K and leaving 1,557,804 shares worth $34.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1897.

Goldman Sachs first reported a position in ACAD in Q2 2013 and has held it in 52 quarters since. The position peaked at $68.6M in Q3 2017. 341 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

Goldman Sachs held 1,557,804 shares of Acadia Pharmaceuticals worth $34.7M as of Q1 2026.
Goldman Sachs sold 12,247 Acadia Pharmaceuticals shares in Q1 2026, an estimated $293K.
Acadia Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #1897 holding.
Goldman Sachs first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Goldman Sachs's Acadia Pharmaceuticals position peaked at $68.6M in Q3 2017.
341 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.